background
background
Earnings Expectation?
Beat
Meet
Miss
Expected Price Action?
Up
Flat
Down

Ligand Pharmaceuticals Missed Consensus Estimates

Thursday, May 8, 2025 at 7:00 AM ET

Ligand Pharmaceuticals (LGND) reported a loss of $2.21 per share on revenue of $45.33 million for the first quarter ended March 2025. The consensus earnings estimate was $0.14 per share on revenue of $39.39 million. The company missed consensus estimates by 1,678.57% while revenue grew 46.34% on a year-over-year basis.

The company said it continues to expect 2025 non-GAAP earnings of $6.00 to $6.25 per share on revenue of $180.0 million to $200.0 million. The current consensus earnings estimate is $6.14 per share on revenue of $192.69 million for the year ending December 31, 2025.

Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Earnings Whisper Grade
Earnings Whisper GradeEarningsWhisper®edarG-
Power Rating
-
Reported Earnings
$-2.21
Earnings Whisper®
-
Consensus Estimate
$0.14
Earnings Surprise
-1,678.6%
Earnings Growth
-376.3%
Reported Revenue
$45.33 Mil
Revenue Estimate
$39.39 Mil
Revenue Surprise
15.1%
Revenue Growth
46.3%